Efficacy Evaluation of Hydrolyzed Collagen Peptide on Knees, Hips, and Ankle Pain in Osteoarthritis
Primary Purpose
Pain, Joint
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Hydrolyzed Collagen Peptide
Sponsored by
About this trial
This is an interventional supportive care trial for Pain, Joint
Eligibility Criteria
Inclusion Criteria:
- Male and female individuals with osteoarthritis on knee who are aged between 45-60 years old,
- Who are not drug-naïve to osteoarthritis and related conditions,
- Volunteers who have ability to communicate adequately with the investigator and in agreement to comply with the study requirements,
- Volunteers who have normal blood pressure and heart rate measured under stabilised conditions at the screening visit after at least 5 minutes of rest under supine position: SBP within 100 to 140 mmHg, DBP within 60 to 90 mmHg and HR within 50 to 100 bpm at least after 5 minutes of rest,
- Volunteers who have understanding of the study and agreement to give a written informed consent.
Exclusion Criteria:
- Who have atopic constitution or asthma and/or known allergy for bovine derived collagen products and/or other any of the excipients of the product.
- Who have hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption.
- Who have an active rheumatoid arthritis or any other inflammatory arthritic condition that researchers consider non appropriate.
- Who have Diabetes Mellitus.
- Who have the use of oral retinoids or oral steroids in the 6 months prior to initiation of the study.
- Who have current participation in another clinical study, or participation in a relevant study within 3 months.
- Who have any history or presence of serious or life-threatening conditions of cardiovascular, neurological, haematological, hepatic, gastrointestinal, renal, pulmonary, endocrinological, metabolism or psychiatric disease, any type of porphiria.
- Who have the presence or history of malabsorption or any gastrointestinal surgery except appendectomy or except herniotomy.
- Who are planned to go or already went under a joint-related reconstructive surgery,
- For female volunteers, who had undergone, or planned to undergo, pregnancy or breastfeeding.
- Who have current or regular intake of NSAIDS, contraceptives, hormones, obesity drugs, absorption inhibitors or antidepressants
- Who are suspected to have a high probability of non-compliance to the study procedure and/or completion of the study according to the investigator's judgment.
- Who have history of drug abuse.
- Who have relationship to the investigator.
- Who are not suitable to any of inclusion criteria.
- Who have history of difficulty of swallowing.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Hydrolized Collagen Peptide
Placebo
Arm Description
This arm will be allocated randomly and receive 10 g hydrolized collagen peptide (Investigational Product) daily throughout the study.
This arm will be allocated randomly and receive placebo daily throughout the study.
Outcomes
Primary Outcome Measures
Amelioration on Knee Pain
Amelioration on knee joint pain, stiffness and physical function according to WOMAC (The Western Ontario and McMaster Universities Osteoarthritis Index) score.
Secondary Outcome Measures
Amelioration on Hip Pain
Amelioration on pain, stiffness and physical function of joints of hip according to WOMAC score.
Amelioration on Ankle Pain
Amelioration on pain and physical function of ankles according to AOFASAHFS (American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Scale) scale.
Full Information
NCT ID
NCT05369780
First Posted
May 6, 2022
Last Updated
May 6, 2022
Sponsor
Sel Sanayi Urunleri Ticaret ve Pazarlama A.S.
Collaborators
Alpan Farma Ar-Ge Biyoteknolojileri Ltd.Sti.
1. Study Identification
Unique Protocol Identification Number
NCT05369780
Brief Title
Efficacy Evaluation of Hydrolyzed Collagen Peptide on Knees, Hips, and Ankle Pain in Osteoarthritis
Official Title
A Multiple-Dose, Randomized, Double-Blinded, Placebo Controlled Trial To Evaluate The Efficacy Of Hydrolyzed Collagen Peptide On Knees, Hips, and Ankle Pains In Adults With Osteoarthritis
Study Type
Interventional
2. Study Status
Record Verification Date
May 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
May 15, 2022 (Anticipated)
Primary Completion Date
May 15, 2023 (Anticipated)
Study Completion Date
May 15, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Sel Sanayi Urunleri Ticaret ve Pazarlama A.S.
Collaborators
Alpan Farma Ar-Ge Biyoteknolojileri Ltd.Sti.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this study is to evaluate the effectiveness of Hydrolyzed collagen peptides on joint pain, stiffness and physical function in adults with osteoarthritis who have complaints on knee joints together with hip and ankles. The assessment of improvements on volunteers' quality of life, and safety and tolerability of the product is the other objective of this placebo-controlled, randomized study.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Joint
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
160 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Hydrolized Collagen Peptide
Arm Type
Experimental
Arm Description
This arm will be allocated randomly and receive 10 g hydrolized collagen peptide (Investigational Product) daily throughout the study.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
This arm will be allocated randomly and receive placebo daily throughout the study.
Intervention Type
Dietary Supplement
Intervention Name(s)
Hydrolyzed Collagen Peptide
Other Intervention Name(s)
Collagen
Intervention Description
Dietary Hydrolized Collagen Peptide sourced from bovine
Primary Outcome Measure Information:
Title
Amelioration on Knee Pain
Description
Amelioration on knee joint pain, stiffness and physical function according to WOMAC (The Western Ontario and McMaster Universities Osteoarthritis Index) score.
Time Frame
2 months
Secondary Outcome Measure Information:
Title
Amelioration on Hip Pain
Description
Amelioration on pain, stiffness and physical function of joints of hip according to WOMAC score.
Time Frame
2 months
Title
Amelioration on Ankle Pain
Description
Amelioration on pain and physical function of ankles according to AOFASAHFS (American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Scale) scale.
Time Frame
2 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female individuals with osteoarthritis on knee who are aged between 45-60 years old,
Who are not drug-naïve to osteoarthritis and related conditions,
Volunteers who have ability to communicate adequately with the investigator and in agreement to comply with the study requirements,
Volunteers who have normal blood pressure and heart rate measured under stabilised conditions at the screening visit after at least 5 minutes of rest under supine position: SBP within 100 to 140 mmHg, DBP within 60 to 90 mmHg and HR within 50 to 100 bpm at least after 5 minutes of rest,
Volunteers who have understanding of the study and agreement to give a written informed consent.
Exclusion Criteria:
Who have atopic constitution or asthma and/or known allergy for bovine derived collagen products and/or other any of the excipients of the product.
Who have hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption.
Who have an active rheumatoid arthritis or any other inflammatory arthritic condition that researchers consider non appropriate.
Who have Diabetes Mellitus.
Who have the use of oral retinoids or oral steroids in the 6 months prior to initiation of the study.
Who have current participation in another clinical study, or participation in a relevant study within 3 months.
Who have any history or presence of serious or life-threatening conditions of cardiovascular, neurological, haematological, hepatic, gastrointestinal, renal, pulmonary, endocrinological, metabolism or psychiatric disease, any type of porphiria.
Who have the presence or history of malabsorption or any gastrointestinal surgery except appendectomy or except herniotomy.
Who are planned to go or already went under a joint-related reconstructive surgery,
For female volunteers, who had undergone, or planned to undergo, pregnancy or breastfeeding.
Who have current or regular intake of NSAIDS, contraceptives, hormones, obesity drugs, absorption inhibitors or antidepressants
Who are suspected to have a high probability of non-compliance to the study procedure and/or completion of the study according to the investigator's judgment.
Who have history of drug abuse.
Who have relationship to the investigator.
Who are not suitable to any of inclusion criteria.
Who have history of difficulty of swallowing.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Aydın Erenmemişoğlu, Prof. Dr.
Phone
+90 532 551 0082
Email
aydin@alpanfarma.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Efficacy Evaluation of Hydrolyzed Collagen Peptide on Knees, Hips, and Ankle Pain in Osteoarthritis
We'll reach out to this number within 24 hrs